There are two separate classes of PAH therapies, the PDE5 inhibitors and the single FDA approved soluble guanylate cyclase activator (riociguat) are available in clinical treatment and both target the NO pathway directly. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.